Form 4: Quest Diagnostics Executive Acquires Shares via Dividend Reinvestment Plan

Mark E. Delaney, SVP & Chief Commercial Officer at Quest Diagnostics, reported the acquisition of 17 shares of common stock through a dividend reinvestment plan.

Summary

• Mark E. Delaney, the Senior Vice President and Chief Commercial Officer of Quest Diagnostics Inc. (DGX), acquired 17 shares of the company's common stock.
• The transaction occurred on July 21, 2025, with each share acquired at a price of $167.491.
• These shares were obtained through a dividend reinvestment plan administered by the reporting person's broker.
• Following this acquisition, Mr. Delaney directly beneficially owns a total of 7,515 shares of Quest Diagnostics common stock.
• The transaction was reported early on this Form 4, despite being eligible for deferred reporting on Form 5 under Rule 16a-6.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The acquisition of shares by a senior executive, even a small amount through a DRIP, indicates continued confidence in the company. The early reporting also reflects good transparency. However, the small scale of the transaction limits its overall impact on sentiment.

Positives

• An executive acquired additional shares in the company, which can signal continued confidence in the company's future performance.
• The shares were acquired through a dividend reinvestment plan, indicating a long-term investment approach.
• The reporting person chose to report the transaction early on Form 4, demonstrating transparency beyond minimum regulatory requirements.

Negatives

• The number of shares acquired (17) is relatively small, suggesting a routine transaction rather than a significant new investment by the executive.

Future Outlook

This filing is an insider transaction report and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

Industry Context

This filing details a routine insider transaction for a senior executive at a healthcare diagnostics company. Such transactions, particularly those involving dividend reinvestment plans, are common across various industries and reflect individual investment decisions rather than broad industry trends.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• Shareholders: May view the insider acquisition as a positive signal of management's continued confidence in the company's value and prospects.
• Employees: No direct impact on employees' roles or compensation.
• Customers: No direct impact on customer services or relations.
• Suppliers: No direct impact on supplier relationships or contracts.
• Creditors: No direct impact on the company's debt obligations or creditworthiness.

Key Dates

Recommendation

This Form 4 reports a routine acquisition of a small number of shares by a senior executive through a dividend reinvestment plan. While it reflects an insider's ongoing investment and confidence, the transaction's size is not substantial enough to signal a significant change in the company's fundamentals or warrant a strong buy or sell recommendation. It is a standard part of executive compensation and investment activity, suggesting a 'hold' position is appropriate based solely on this filing.

Keywords

Quest Diagnostics, DGX, Insider Transaction, Form 4, Share Acquisition, Dividend Reinvestment Plan, Executive Ownership